Advertisement

Women and Coronary Artery Disease

  • JoAnne Micale Foody
Chapter
Part of the Contemporary Cardiology book series (CONCARD)

Abstract

Heart disease is the leading cause of mortality among women in the United States 500,000 women each year die of heart disease; more than twice the number of deaths caused by all cancers combined (1). Approximately one out of every two women in the United States will die from some cardiovascular event most likely, myocardial infarction (MI), hypertensive heart disease, or stroke (1). The clinical presentation of heart disease (2,3), the impact of individual coronary risk factors (1,(4, 5, 6, 7) and the results of their interventions differ dramatically by gender (8, 9, 10, 11, 12, 13, 14, 15, 16, 17). This chapter reviews the uniquely female attributes that are associated with differences in disease presentation, that attenuate coronary risk, and that modulate clinical outcomes.

Keywords

Postmenopausal Woman Hypertensive Heart Disease Scandinavian Simvastatin Survival Study Coronary Artery Disease Event Preventive Cardiology 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Anonymous. Major cardiovascular disease (CVD) during 1997–1999 and major CVD hospital discharge rates in 1997 among women with diabetes United States. MMWR Morbidity&Mortality Weekly Report. 2001; 50(43): 948–954.Google Scholar
  2. 2.
    Kuster GM, Buser P, Osswald S, et al. Comparison of presentation, perception, and six-month outcome between women and men > or = 75 years of age with angina pectoris. Am J Cardiol 2003; 91(4): 436–439.PubMedCrossRefGoogle Scholar
  3. 3.
    Lewis SJ. Cardiovascular disease in postmenopausal women: myths and reality. Am J Cardiol 2002; 89(12A): 5E–10E; discussion 10E–11E.PubMedCrossRefGoogle Scholar
  4. 4.
    Knopp RH. Risk factors for coronary artery disease in women. Am J Cardiol 2002; 89(12A): 28E–34E; discussion 34E–35E.PubMedCrossRefGoogle Scholar
  5. 5.
    Kannel WB. The Framingham Study: historical insight on the impact of cardiovascular risk factors in men versus women. J Gend Specif Med 2002; 5(2): 27–37.PubMedGoogle Scholar
  6. 6.
    Bertsias G, Mammas I, Linardakis M, Kafatos A. Overweight and obesity in relation to cardiovascular disease risk factors among medical students in Crete, Greece. BMC Public Health 2003; 3(1): 3.PubMedCrossRefGoogle Scholar
  7. 7.
    Anonymous. Prevalence of selected cardiovascular disease risk factors among American Indians and Alaska Natives United States, 1997. MMWR Morbidity&Mortality Weekly Report 2000; 49(21): 461–465.Google Scholar
  8. 8.
    Vaccarino V. Women and outcomes of coronary artery bypass surgery: do we have an answer? [comment]. Am Heart J 2003; 146(6): 935–937.PubMedCrossRefGoogle Scholar
  9. 9.
    Gorman Koch C, Mora Mangano C, Schwann N, Vaccarino V. Is it gender, methodology, or something else? J Thorac Cardiovasc Surg 2003; 126(4): 932–935.PubMedCrossRefGoogle Scholar
  10. 10.
    Abramson JL, Veledar E, Weintraub WS, Vaccarino V. Association between gender and in-hospital mortality after percutaneous coronary intervention according to age. Am J Cardiol 2003; 91(8): 968–971, A964.PubMedCrossRefGoogle Scholar
  11. 11.
    Smith GL, Masoudi FA, Vaccarino V, Radford MJ, Krumholz HM. Outcomes in heart failure patients with preserved ejection fraction: mortality, readmission, and functional decline [see comment]. J Am Coll Cardiol 2003; 41(9): 1510–1518.PubMedCrossRefGoogle Scholar
  12. 12.
    Vaccarino V, Abramson JL, Veledar E, Weintraub WS. Sex differences in hospital mortality after coronary artery bypass surgery: evidence for a higher mortality in younger women. Circulation 2002; 105(10): 1176–1181.PubMedCrossRefGoogle Scholar
  13. 13.
    Vaccarino V, Parsons L, Every NR, Barron HV, Krumholz HM. Sex-based differences in early mortality after myocardial infarction. National Registry of Myocardial Infarction 2 Participants. [see comment]. N Engl J Med 1999; 341(4): 217–225.PubMedCrossRefGoogle Scholar
  14. 14.
    Vaccarino V, Chen YT, Wang Y, Radford MJ, Krumholz HM. Sex differences in the clinical care and outcomes of congestive heart failure in the elderly. Am Heart J 1999; 138(5Pt 1): 835–842.PubMedCrossRefGoogle Scholar
  15. 15.
    Krumholz HM, Philbin DM Jr, Wang Y, et al. Trends in the quality of care for Medicare beneficiaries admitted to the hospital with unstable angina. [see comment]. J Am Coll Cardiol 1998; 31(5): 957–963.PubMedCrossRefGoogle Scholar
  16. 16.
    Nohria A, Vaccarino V, Krumholz HM. Gender differences in mortality after myocardial infarction. Why women fare worse than men. Cardiol Clin 1998; 16(1): 45–57.PubMedCrossRefGoogle Scholar
  17. 17.
    Vaccarino V, Krumholz HM, Mendes de Leon CF, et al. Sex differences in survival after myocardial infarction in older adults: a community-based approach. [see comment]. J Am Geriatr Soc 1996; 44(10): 1174–1182.PubMedGoogle Scholar
  18. 18.
    Wenger NK. Coronary risk reduction in the menopausal woman. Rev Port Cardiol 1999; 18(Suppl 3): 39–47.Google Scholar
  19. 19.
    Mukherjee D, Hsu A, Moliterno DJ, Lincoff AM, Goormastic M, Topol EJ. Risk factors for premature coronary artery disease and determinants of adverse outcomes after revascularization in patients < or =40 years old. Am J Cardiol 2003; 92(12): 1465–1467.PubMedCrossRefGoogle Scholar
  20. 20.
    Cole JH, Miller JI 3rd, Sperling LS, Weintraub WS. Long-term follow-up of coronary artery disease presenting in young adults. [see comment]. J Am Coll Cardiol 2003; 41(4): 521–528.PubMedCrossRefGoogle Scholar
  21. 21.
    Lee PY, Alexander KP, Hammill BG, Pasquali SK, Peterson ED. Representation of elderly persons and women in published randomized trials of acute coronary syndromes. JAMA 2001; 286(6): 708–713.PubMedCrossRefGoogle Scholar
  22. 22.
    Hulley SB. The US National Cholesterol Education Program. Adult treatment guidelines. Drugs 1988; 36(Suppl 3): 100–104.PubMedGoogle Scholar
  23. 23.
    Greenlund KJ, Giles WH, Keenan NL, Croft JB, Casper ML, Matson-Koffman D. Prevalence of multiple cardiovascular disease risk factors among women in the United States, 1992 and 1995: the Behavioral Risk Factor Surveillance System. J Womens Health 1998; 7(9): 1125–1133.PubMedGoogle Scholar
  24. 24.
    Rifkind BM, Tamir I, Heiss G, Wallace RB, Tyroler HA. Distribution of high density and other lipoproteins in selected LRC prevalence study populations: a brief survey. Lipids 1979; 14(1): 105–112.PubMedCrossRefGoogle Scholar
  25. 25.
    Bittner V. Lipoprotein abnormalities related to women’s health. Am J Cardiol 2002; 90(8A): 771–841.Google Scholar
  26. 26.
    Stensvold I, Urdal P, Thurmer H, Tverdal A, Lund-Larsen PG, Foss OP. High-density lipoprotein cholesterol and coronary, cardiovascular and all cause mortality among middle-aged Norwegian men and women. Eur Heart J 1992; 13(9): 1155–1163.PubMedGoogle Scholar
  27. 27.
    Kannel WB, McGee D, Gordon T. A general cardiovascular risk profile: the Framingham Study. Am J Cardiol 1976; 38(1): 46–51.PubMedCrossRefGoogle Scholar
  28. 28.
    Wilson PW, Garrison RJ, Castelli WP, Feinleib M, McNamara PM, Kannel WB. Prevalence of coronary heart disease in the Framingham Offspring Study: role of lipoprotein cholesterols. Am J Cardiol 1980; 46(4): 649–654.PubMedCrossRefGoogle Scholar
  29. 29.
    Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. [see comment]. Circulation 1998; 97(18): 1837–1847.PubMedGoogle Scholar
  30. 30.
    Livshits G, Weisbort J, Meshulam N, Brunner D. Multivariate analysis of the twenty-year follow-up of the Donolo-Tel Aviv Prospective Coronary Artery Disease Study and the usefulness of high density lipoprotein cholesterol percentage. Am J Cardiol 1989; 63(11): 676–681.PubMedCrossRefGoogle Scholar
  31. 31.
    Brunner D, Weisbort J, Meshulam N, et al. Relation of serum total cholesterol and high-density lipoprotein cholesterol percentage to the incidence of definite coronary events: twenty-year follow-up of the Donolo-Tel Aviv Prospective Coronary Artery Disease Study. Am J Cardiol 1987; 59(15): 1271–1276.PubMedCrossRefGoogle Scholar
  32. 32.
    Walden CE, Knopp RH, Wahl PW, Beach KW, Strandness E Jr. Sex differences in the effect of diabetes mellitus on lipoprotein triglyceride and cholesterol concentrations. N Engl J Med 1984; 311(15): 953–959.PubMedCrossRefGoogle Scholar
  33. 33.
    Colditz GA, Manson JE, Hankinson SE. The Nurses’ Health Study: 20-year contribution to the understanding of health among women. J Womens Health 1997; 6: 49–62.PubMedCrossRefGoogle Scholar
  34. 34.
    Dubbert PM, Carithers T, Sumner AE, et al. Obesity, physical inactivity, and risk for cardiovascular disease. Am J Med Sci 2002; 324(3): 116–126.PubMedCrossRefGoogle Scholar
  35. 35.
    Kohl HW3rd. Physical activity and cardiovascular disease: evidence for a dose response. Med Sci Sports Exerc 2001; 33(6 Suppl): S472–483; discussion S493–474.PubMedGoogle Scholar
  36. 36.
    Lawler JM, Hu Z, Green JS, Crouse SF, Grandjean PW, Bounds RG. Combination of estrogen replacement and exercise protects against HDL oxidation in post-menopausal women. Int J Sports Med 2002; 23(7): 477–483.PubMedCrossRefGoogle Scholar
  37. 37.
    Lowensteyn I, Coupal L, Zowall H, Grover SA. The cost-effectiveness of exercise training for the primary and secondary prevention of cardiovascular disease. J Cardiopulm Rehabil 2000; 20(3): 147–155.PubMedCrossRefGoogle Scholar
  38. 38.
    Smith SC Jr, Amsterdam E, Balady GJ, et al. Prevention Conference V: Beyond secondary prevention: identifying the high-risk patient for primary prevention: tests for silent and inducible ischemia: Writing Group II. Circulation 2000; 101(1): E12–16.PubMedGoogle Scholar
  39. 39.
    Thompson PD, Buchner D, Pina IL, et al. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity). [see comment]. Circulation 2003; 107(24): 3109–3116.PubMedCrossRefGoogle Scholar
  40. 40.
    Wannamethee SG, Shaper AG. Physical activity in the prevention of cardiovascular disease: an epidemiological perspective. Sports Med 2001; 31(2): 101–114.PubMedCrossRefGoogle Scholar
  41. 41.
    Wenger NK. Preventive coronary interventions for women. Med Sci Sports Exerc 1996; 28(1): 3–6.PubMedCrossRefGoogle Scholar
  42. 42.
    Whitlock EP, Williams SB. The primary prevention of heart disease in women through health behavior change promotion in primary care. Womens Health Issues 2003; 13(4): 122–141.PubMedCrossRefGoogle Scholar
  43. 43.
    Miller TD, Fletcher GF. Exercise and coronary artery disease prevention. Cardiologia 1998; 43(1): 43–51.PubMedGoogle Scholar
  44. 44.
    Miller TD, Balady GJ, Fletcher GF. Exercise and its role in the prevention and rehabilitation of cardiovascular disease. Ann Behav Med 1997; 19(3): 220–229.PubMedCrossRefGoogle Scholar
  45. 45.
    Grundy SM, Bazzarre T, Cleeman J, et al. Prevention Conference V: Beyond secondary prevention: identifying the high-risk patient for primary prevention: medical office assessment: Writing Group I. Circulation 2000; 101(1): E3–E11.PubMedGoogle Scholar
  46. 46.
    Mosca L, Appel L, Benjamin E, et al. Evidence-based guidelines for cardiovascular disease prevention in women. Circulation 2004; 109: 672–693.PubMedCrossRefGoogle Scholar
  47. 47.
    Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. JAMA 1998; 279: 1615–1622.PubMedCrossRefGoogle Scholar
  48. 48.
    No authors listed. Influence of Pravastatin and Plasma Lipids on Clinical Events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998; 97(15): 1440–1445.Google Scholar
  49. 49.
    Scandinavian Simvastatin Survival Study Group: randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–1389.Google Scholar
  50. 50.
    Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. The Cholesterol and Recurrent Events Trial Investigators. N Engl J Med 1996; 335: 1001–1009.PubMedCrossRefGoogle Scholar
  51. 51.
    Grady D, Applegate W, Bush T, Furberg C, Riggs B, Hulley SB. Heart and Estrogen/progestin Replacement Study (HERS): design, methods, and baseline characteristics. Control Clin Trials 1998; 19(4): 314–335.PubMedCrossRefGoogle Scholar
  52. 52.
    Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/Progestin Replacement Study follow-up (HERS II). [see comment] [erratum appears in JAMA 2002;288(9):1064]. JAMA 2002; 288(1): 49–57.PubMedCrossRefGoogle Scholar
  53. 53.
    Hays J, Ockene JK, Brunner RL, et al. Effects of estrogen plus progestin on health-related quality of life. [see comment]. N Engl J Med 2003; 348(19): 1839–1854.PubMedCrossRefGoogle Scholar
  54. 54.
    Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. [see comment] [summary for patients in CMAJ 2002;167(4):377-378]. JAMA 2002; 288(3): 321–333.PubMedCrossRefGoogle Scholar
  55. 55.
    Anonymous. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. [see comment] [erratum appears in JAMA 1995;274(21):1676]. JAMA 1995; 273(3): 199–208.CrossRefGoogle Scholar
  56. 56.
    Hemminki E, McPherson K. Impact of postmenopausal hormone therapy on cardiovascular events and cancer: pooled data from clinical trials. [see comment]. BMJ 1997; 315(7101): 149–153.PubMedGoogle Scholar
  57. 57.
    Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. [see comment]. JAMA 1998; 280(7): 605–613.PubMedCrossRefGoogle Scholar
  58. 58.
    Cherry N, Gilmour K, Hannaford P. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomized placebo controlled trial. Lancet Available at: http://image.thelancet.com/extras/02art11268web.pdf.
  59. 59.
    Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. [see comment]. N Engl J Med 2000; 343(8): 522–529.PubMedCrossRefGoogle Scholar
  60. 60.
    Herrington DM, Howard TD, Hawkins GA, et al. Estrogen-receptor polymorphisms and effects of estrogen replacement on high-density lipoprotein cholesterol in women with coronary disease. [see comment]. N Engl J Med 2002; 346(13): 967–974.PubMedCrossRefGoogle Scholar
  61. 61.
    Waters DD, Alderman EL, Hsia J, et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. [see comment]. JAMA 2002; 288(19): 2432–2440.PubMedCrossRefGoogle Scholar
  62. 62.
    Hurn PD, Brass LM. Estrogen and stroke: a balanced analysis. Stroke 2003; 34(2): 338–341.PubMedCrossRefGoogle Scholar
  63. 63.
    Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI. A clinical trial of estrogenreplacement therapy after ischemic stroke. [see comment]. N Engl J Med 2001; 345(17): 1243–1249.PubMedCrossRefGoogle Scholar
  64. 64.
    Mosca L, Collins P, Herrington DM, et al. Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. [see comment]. Circulation 2001; 104(4): 499–503.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc., Totowa, NJ 2006

Authors and Affiliations

  • JoAnne Micale Foody
    • 1
  1. 1.Section of Cardiovascular Medicine, Department of Internal MedicineYale University School of MedicineNew Haven

Personalised recommendations